Showing 2732 results for "amyotrophic lateral sclerosis (ALS)"

#AANAM – Better REFALS Trial Response Seen in ALS Patient Group

Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Amyotrophic lateral sclerosis (ALS) patients with a short disease duration and fast progression showed better responses to Orion’s investigational oral…

Actimed Plans to Advance Treatment for Muscle Wasting in ALS

Actimed Therapeutics is developing S-oxprenolol to prevent muscle wasting and body mass loss due to amyotrophic lateral sclerosis (ALS), using proceeds from a recent license agreement with Faraday Pharmaceuticals. Under the agreement, Faraday acquired global rights to develop and commercialize S-oxprenolol for muscle-affecting disorders other than ALS, particularly…

Amylyx to Seek AMX0035’s Approval in Europe

Amylyx Pharmaceuticals is planning to file an application by the end of this year requesting that the European Medicines Agency (EMA) approve AMX0035 as an oral treatment for amyotrophic lateral sclerosis (ALS). This follows a recent announcement that a similar application will be submitted to Health…